Abstract B32: T cell receptor-like chimeric antigen-receptor to recognize neoepitopes derived from driver mutations
Authors: Hou Yafei , Hou David 
Published: December 2022

Abstract
BACKGROUND: T cell receptor (TCR)-based cell therapy to treat solid tumors by targeting tumor neoantigens is gaining momentum. While there is an urgent need for discovering novel TCRs, one challenge is that the exogenous TCR may compete with the endogenous TCR for CD3 signaling components and form mixed dimers with potential toxicities. Additionally, the activity of T cells highly depends on signaling machinery only present in T cells, which restricts the scope of eligible therapeutic cells. We developed a TCR-like chimeric antigen-receptor to both overcome the mispairing of TCR α/β chains and to expand the scope of TCR-based cell therapy to other immune cells. METHOD: To identify novel TCRs, a monoclonal TCR discovery platform was developed. A high avidity TCR of a neoepitope-specific CD8+ T cell clone (CTL) that was generated from donor PBMCs was isolated and sequenced. A chimeric antigen-receptor comprising an antigen binding domain (which is a portion of the identified TCR), a CD28 segment containing the hinge/transmembrane domain, and a cytoplasmic signaling domain containing a Dap10 and a Dap12 intracellular domains. To augment the avidity of the antigen receptor, a chimeric co-receptor was constructed by combining HLA-I binding domains of CD8α with the hinge/transmembrane/cytoplastic domains of CD4. T cell line (J.RT3-T3.5) and NK cell line (KYGH-1) were transduced by a lentivirus encoding the chimeric antigen-receptor and co-receptor to assess their expression and function. RESULTS: Two novel TCRs specific for CTNNB1S37F peptide (YLDSGIHFGA) and for p53R175H peptide (HMTEVVRHC) respectively were identified; both are high-avidity and can recognize the endogenous neoepitope presented by HLA-A2 in tumor cells. A chimeric antigen-receptor specific for CTNNB1S37F neoepitope/HLA-A2 was expressed on the surface of 293T cells independent of endogenous CD3. However, its avidity to recognize CTNNB1S37F neoepitope was approximately 5 folds lower than that of the native TCR. Co-expression of the co-receptor could significantly enhance the avidity of the chimeric antigen-receptor and make it capable of recognizing endogenously presented neoepitope in tumor cells. In addition, NK cells re-directed with the TCR-like chimeric antigen-receptor could also recognize the neoepitope peptide in the context of HLA-A2. CONCLUSION: We validated a TCR-like chimeric antigen-receptor that can be expressed on cells independent of endogenous CD3 and can recognize neoepitope/HLA-A2. We also designed and tested a co-receptor that can enhance the avidity of the chimeric antigen-receptor. To further leverage the avidity of the TCR-like chimeric antigen-receptor, testing of new configurations of the chimeric antigen-receptor and co-receptor is underway.
Citation Format: Yafei Hou, David Hou. T cell receptor-like chimeric antigen-receptor to recognize neoepitopes derived from driver mutations [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr B32.